Decreased choroidal thickness could increase VEGF

Article

Decreased choroidal thickness could increase vascular endothelial growth factor (VEGF) and cause tissue hypoxia.

Decreased choroidal thickness could increase vascular endothelial growth factor (VEGF) and cause tissue hypoxia.

Dr Giuseppe Querques et al., Department of Ophthalmology, University Vita Salute San Raffaele, Milan, Italy, studied a total of 63 eyes of 63 diabetic patients either without diabetic retinopathy (NDR), with diabetic retinopathy [nonproliferative diabetic retinopathy (NPDR)] and no clinically significant macular oedema (CSME).

The mean best-corrected visual acuity was 0.13 ± 0.25 LogMAR and the mean central macular thickness (CMT) was 272.5 ± 16.2 μm in 21 NDR eyes, 294.5 ± 23.5 μm in 21 NPDR/CSME− eyes, and 385.6 ± 75.1 μm in 21 NPDR/CSME+ eyes.

There were no differences in mean subfoveal choroidal thickness between each diabetic group. However, in each diabetic group the mean subfoveal choroidal thickness was significantly reduced compared to the control group.

An overall thinning of the choroid on EDI OCT was witnessed in diabetic eyes. This could lead to tissue hypoxia and could increase VEGF levels, meaning the blood-retinal barrier could break down and cause macular oedema.

The abstract for the study was printed in the Investigative Journal of Ophthalmology.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.